Family offices are an investor class that has recently garnered a lot of attention from life science entrepreneurs. Their wide variety of motivations and transaction types and generally speaking, more flexible term sheets, make these investors a great partner for biotech companies undertaking the daunting task of commercializing therapeutic products.
At RESI, the Biotech Family Office Panel will provide insights into each represented firm’s current interests and outlook on the biotech sector, how they source and evaluate deals and their position in the investment ecosystem.
Catherine Love, Director, Capital Services, MaRS Discovery District
Catherine Love is Director of Capital Services for MaRS Discovery District, where she focuses on helping companies raise Series A to later rounds of financing, alongside developing and expanding MaRS’ relationships with Canadian and international investors. Catherine has more than 15 years of experience focused on Health Technology investing including Senior Investor Relations roles with Medicago and MDS Inc., Director of Life Sciences Venture Capital for BDC Venture Capital, and Pharmaceutical & Biotechnology Equity Research Analyst with Research Capital. She also has significant experience building not-for-profit life science industry organizations and currently serves on the Leadership Team of CELS San Francisco. Catherine holds a B.Sc. in Biochemistry from McGill University, an M.Sc. in Organic Chemistry from the University of Toronto and the CFA Charter designation.
Chuck Stetson, CEO, Stetson Family Office
Chuck’s grandfather, Eugene W. Stetson, started the Stetson Family Office shortly after he personally led the buyout of The Coca-Cola Company through a public offering in August 1919 by the Guaranty Trust Company of New York, where he subsequently served as Chairman. At his death, Eugene was Coca-Cola’s longest serving member of the Board and member of the Executive Committee. Chuck, the third generation running the family office, is an entrepreneur, venture capitalist, and philanthropist.
The Stetson Family Office started Healthcare Impact Foundation, a 501-c-3 organization, in 2017 to bring capital and management expertise to life science companies at all stages and to build and maintain an efficient life science eco-system composed of R&D facilities, incubation facilities, venture capital investors, family office investors, and networks of experts in science, management, industry, reimbursement and public policy.
Stetson Family Office is setting up a Global Family Office BioForum with family offices around the globe working closely with their local healthcare innovation. Family Offices are responding with excitement. Insead School of Business of Singapore at their 3rd Asian Family Office Day in 2015 had Chuck as their featured luncheon speaker. The Association for Corporate Growth recently asked Chuck to lead their global Family Office Council initiative which involves bringing together family offices from around the globe that are interested in small to medium size buyouts and growth equity.
David Ramos, CFO, AGP Holdings
David is a Public Accountant by Instituto Tecnológico Autónomo de México (ITAM), has a diploma as a Corporate Advisor awarded by the same Institution and obtained the degree of Master in Tax Law from Universidad Panamericana. He is a member of the International Fiscal Association (IFA) –Chapter Mexico–; obtained a certification as C.P.A. specialized in Tax matters by Instituto Mexicano de Contadores Públicos (IMPC); and has served as representative of the Chair of the Finance and Taxes Committee in the National Chamber of the Transformation Industry (CANACINTRA – Cámara Nacional de la Industria de Transformación) in the State of Puebla, Mexico. For over 15 years as an advisor for Mexican and International taxation, David has provided timely, effective and efficient tax solutions. He has collaborated in the implementation of corporate restructurings; financial planning; M&A; Tax Due Diligence for sale or acquisition of target companies; in advising HNWI for successful succession structures; and, in general, is experienced in providing solutions that allow an efficient tax burden in benefit of individuals, companies and their shareholders. He currently serves as Chief Financial Officer (CFO) in a Mexican Family Office, being responsible for planning and managing the Family’s corporate structures and international investment structures by following their strategic plan and vision, long-term investment policies, as well as for assuring compliance for investment commitments or credits that investment vehicles may have acquired.
Oded Levi, President, Epstein Enterprises
Oded is the President of Epstein Enterprises Inc., a single family office based in Toronto. EEI is a multi-faceted investment company with direct and indirect investments in private and public corporations as well as commercial and residential real estate. EEI’s technology investments span pre-revenue through growth stage. EEI looks to support companies as they develop, grow and mature. In the past, Oded has played executive management and CFO roles at a number of EEI’s operating subsidiaries and continues to work closely with leaders of those enterprises. Prior to coming to EEI in 2006, Oded worked at Arthur Andersen, Deloitte and a boutique investment research firm. Oded is a CPA, CA and has a BBA in Accounting and MBA in Finance from the Schulich School of Business at York University. He has served on the boards of public, private and not for profit organizations.
Sherry Grisewood, Chief Investment Officer, Foxhill Asset Management
Sherry has over 30 years’ experience as a Wall Street professional in investment banking, advisory and research capacities across a wide variety of equity investment and corporate-directed advisory activities, primarily for early stage life science, med-device and related technology companies. She has participated in over 80 transactions involving initial public offerings, secondaries, private placements and M&A. Through her extensive corporate and academic interactions, Sherry has developed particular focus in therapeutic areas where there is an intersection of technologies such as in regenerative medicine, nucleic acid-based technologies, immunotherapy and therapeutic medical devices that are being developed by US and ex-US life science companies.
Sherry has been active at the Board level for several early stage life science and medical device companies over the last 20 years, and currently chairs the Audit Committee and is a member of the Compensation Committee for Tapimmune, Inc., a NASDAQ-listed cancer immunotherapy company and is a member of the Board for Mobitech Regenerative Medicine, Inc., an early stage orthopedics device company. She holds a Bachelor of Science degree with Highest Honors from Ramapo College of New Jersey and holds the Chartered Financial Analyst designation. Sherry holds FINRA general securities, investment banking and research principals licenses, is a member of the CFA Institute, the Tissue Engineering and Regenerative Medicine Society International (TERMIS), the American Society of Gene and Cell Therapy, the European Federation of Biotechnology, Women in Bio and the Jazz Society of New Jersey.